These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37087410)

  • 1. Interim PET in follicular lymphoma: more patience, please.
    Procházka V
    Ann Hematol; 2023 Jul; 102(7):1953-1954. PubMed ID: 37087410
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma.
    Barrington SF; Trotman J
    Lancet Haematol; 2021 Jan; 8(1):e80-e93. PubMed ID: 33357487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline PET as prognostic index in diffuse large B-cell lymphoma and grade IIIb follicular lymphoma: a retrospective study of a single-center experience.
    Campiotti L; DE Palma D; Guasti L; Proserpio I; Casagrande S; Schiorlin I; Bolzacchini E; Suter M; Ogliari F; Squizzato A
    Q J Nucl Med Mol Imaging; 2021 Mar; 65(1):59-63. PubMed ID: 30781938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.
    Adams HJA; Kwee TC
    Semin Oncol; 2017 Dec; 44(6):404-419. PubMed ID: 29935902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of 18F-FDG PET/CT in evaluating the efficacy of chemotherapy for diffuse large B-cell lymphoma with cardiac involvement.
    Yang Y; Chen P; Liu L; Lin J; Huang S
    J Nucl Cardiol; 2022 Dec; 29(6):3548-3553. PubMed ID: 33660215
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma.
    Johansson P; Alig S; Richter J; Hanoun C; Rekowski J; Dürig J; Ylstra B; de Jong D; Klapper W; Alizadeh AA; Dührsen U; Hüttmann A
    Ann Hematol; 2023 Dec; 102(12):3445-3455. PubMed ID: 37566280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
    Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
    J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy.
    Cox MC; Ambrogi V; Lanni V; Cavalieri E; Pelliccia S; Scopinaro F; Monarca B; Marchetti P; Spiriti MA
    Leuk Lymphoma; 2012 Feb; 53(2):263-9. PubMed ID: 21846184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma.
    Hüttmann A; Müller S; Jöckel KH; Dührsen U
    J Clin Oncol; 2010 Sep; 28(27):e488-9; author reply e490-1. PubMed ID: 20644097
    [No Abstract]   [Full Text] [Related]  

  • 11. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
    Mylam KJ; Kostakoglu L; Hutchings M; Coleman M; Lamonica D; Czuczman MS; Diehl LF; Nielsen AL; Jensen P; Loft A; Hendel HW; Iyer V; Leppä S; Jyrkkiö S; Holte H; Eriksson M; Gillstrøm D; Hansen PB; Seppänen M; Hjorthaug K; Brown Pde N; Pedersen LM
    Leuk Lymphoma; 2015 Jul; 56(7):2005-12. PubMed ID: 25330442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
    Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
    J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Moskowitz CH; Zelenetz A; Schoder H
    J Natl Compr Canc Netw; 2010 Mar; 8(3):347-52. PubMed ID: 20202464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of interim 18F-FDG PET-CT examination in evaluation of chemotherapy response and prognosis in patients with diffuse large B-cell lymphoma].
    Ding C; Li T; Fan L; Xu W; Li J; Sun J; Ding Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):342-4. PubMed ID: 24759025
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
    Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I
    Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both Interim and End-of-Treatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography Scans Have Low Value in Diffuse Large B-Cell Lymphoma.
    Adams HJ; Kwee TC
    J Clin Oncol; 2016 Mar; 34(7):765-6. PubMed ID: 26755517
    [No Abstract]   [Full Text] [Related]  

  • 19. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure.
    Ng AP; Wirth A; Seymour JF; Lee M; Hogg A; Januszewicz H; Wolf M; Prince HM; Macmanus M; Hicks RJ
    Leuk Lymphoma; 2007 Mar; 48(3):596-600. PubMed ID: 17454604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim18 F-FLUORO-2-deoxy-d-glucose positron emission tomography scan/computed tomography scan in diffuse large B cell lymphoma-as a prognostic tool.
    Basit A; Siddiqui N; Muzaffar N; Awan UK; Bashir H; Khan SA; Hameed A
    J Pak Med Assoc; 2016 Apr; 66(4):380-6. PubMed ID: 27122261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.